Stryker Corporation (SYK) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Sell if holding. Momentum 1.0/10 is below the 5.0 floor at $305.23 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Supplier: sole-source raw materials and services.
Stryker is a global medical technology company with two segments: MedSurg and Neurotechnology (62% of $25.1B 2025 net sales) and Orthopaedics (38%), selling surgical equipment, instruments, endoscopy, patient handling, neurovascular, and joint replacement products in ~61... Read more
Sell if holding. Momentum 1.0/10 is below the 5.0 floor at $305.23 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Supplier: sole-source raw materials and services. Chart setup: Death cross, below all MAs, RSI 14, MACD bearish. Score 4.9/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole-source raw materials and services10-K Item 1A: 'several raw materials, components, finished devices and services are procured from a sole source due to, among other things, the quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.0/10 is below the 5.0 floor at $305.23 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Consecutive earnings misses (2); Concentration risk — Supplier: sole-source raw materials and services. Chart setup: Death cross, below all MAs, RSI 14, MACD bearish. Prior stop was $293.15. Score 4.9/10, moderate confidence.
Take-profit target: $377.20 (+24.2% upside). Prior stop was $293.15. Stop-loss: $293.15.
Concentration risk — Supplier: sole-source raw materials and services; Consecutive earnings misses (2); Weak overall score: 4.9/10.
Stryker Corporation trades at a P/E of 37.5 (forward 18.8). TrendMatrix value score: 5.3/10. Verdict: Sell.
36 analysts cover SYK with a consensus score of 4.1/5. Average price target: $419.
What does Stryker Corporation do?Stryker is a global medical technology company with two segments: MedSurg and Neurotechnology (62% of $25.1B 2025 net...
Stryker is a global medical technology company with two segments: MedSurg and Neurotechnology (62% of $25.1B 2025 net sales) and Orthopaedics (38%), selling surgical equipment, instruments, endoscopy, patient handling, neurovascular, and joint replacement products in ~61 countries. Products marketed directly to doctors, hospitals, and healthcare facilities, with Mako robotic-arm technology as a key platform.